News

ISB Annual Report: Catalyzing A Revolution

ISB’s compass has always been oriented toward the future. Even when we reflect on the past year for each annual report, it’s always through the lens of what’s on the horizon. We are remarkably consistent in that regard, which is in no small part due to our president Dr. Lee Hood, whose vision is perpetually a decade – at least – ahead of everyone else.

In this year’s letter, Dr. Hood offers a treatise on the momentum that has tipped his every prediction into a new reality.

As we contemplate his vision for the future of healthcare and scientific wellness, we are reminded of the core values that tether our intrepid researchers to our common foundation as they explore the far reaches of scientific discovery: We cherish intellectual freedom, value collaboration, share what we learn, create roadmaps, and we expect to invent the future of human health, scientific wellness, and environmental sustainability.

What lies ahead is a stretch of this roadmap.

Travel with us.

Read More

Recent Articles

  • Autoimmune Disease and Pregnancy: ISB Study Challenges Prevailing Wisdom, Unveils Nuances

    An ISB-led study showed nuanced pregnancy outcomes for pregnant individuals with autoimmune disease. The findings reinforce that there isn’t a one-size-fits-all approach, and provides important new avenues for further investigation.

  • ISB Building at dusk

    2023 Year in Review

    Throughout 2023, ISB research has been published in impactful peer-reviewed journals and our scientists have been featured in major media outlets and popular podcasts. In this 2023 Year in Review, we showcase some of our most important and interesting highlights of the year.

  • Lifestyle coaching improves cognitive decline in Alzheimer's disease trial.

    Personalized Coaching Decreases Cognitive Decline in Early-Stage Alzheimer’s Disease Patients

    Supplementing the standard of treatment for Alzheimer’s disease patients with personalized lifestyle coaching leads to less cognitive decline compared to standard of treatment alone, according to an ISB-led two-year study. The results were published in the Journal of Alzheimer’s Disease.